

# TABLE OF CONTENTS

December 21, 2009

No. 2169

## BUSINESS

- 1 Hospital Market Key to Success of Prasugrel: Mr Shoda  
- NDA for Edoxaban to Be Filed in Japan within 2010
- 2 Chugai to Enter Diabetes Field in Earnest
- 3 Banyu Launches Japan's 1st DPP-4 Inhibitor Januvia
- 3 GSK to Launch HPV Vaccine Cervarix  
- Aiming at Launching at Least One Novel Vaccine Every Year
- 4 Nippon Chemiphar, Ranbaxy Terminate Alliance
- 4 Januvia Leaps to Top Place on GP Market: Rep Track Survey
- 6 Wholesalers' Primary Profit on Sales - 2.04% in FY2008: Mr Matsutani
- 6 Diversifying Business Not the Cure for "Patent Cliff": Datamonitor
- 7 **BUSINESS NEWS IN BRIEF**  
- Merck Serono Aims at 10% Market Share for hGH Saizen  
- TMX-67 to Drive Teijin's Business: Mr Ohyagi  
- Takara Bio Obtains Patent on Expansion Culture of Lymphocytes  
- CMIC Acquires DS Propharma's Shizuoka Plant

## REGULATORY

- 8 Cut and Thrust About 2% Price Cut for Long-Listed Drugs at *Chuikyo*  
- FPMAJ, PhRMA, EFPIA Happy with *Koroshō's* Premium  
- Reasonable Profits Essential for Drug Markers: Health Minister  
- JMA Member Not Dead Set Against the Premium
- 9 Punishment Proposed by *Koroshō* for Firms That Fail to Develop Requested Drugs  
- Impacts on Individual Companies Simulated  
- Calculation Method for Average Overseas Prices Proposed to Be Relaxed  
- Some Drugs to Be Returned to Piece-Work System: *Koroshō*  
- *Koroshō* Proposes 10% Premium for Biosimilars  
- Industry Task Force Created to Expedite Development of Unapproved Drugs

- 14 *Koroshō* Aims at First Net Increase in Medical Fees in 10 Years
- 14 *Chuikyo* Fails to Reach Consensus on Medical Fee Revision Rate  
- Top-Level Negotiations Start between *Koroshō* and MOF
- 14 **REGULATORY NEWS IN BRIEF**  
- Nippon Shinyaku Submits NDA for Azacitidine for MDS  
- Onbrez Breezhaler Approved for COPD in EU: Novartis  
- Micardis Approved by EC for Reduction of CV Morbidity

## R&D

- 16 Bayer Schering Starts PIII Trial for Flortetaben
- 16 **R&D NEWS IN BRIEF**  
- Dabigatran Shows Non-Inferiority to Warfarin: BI  
- Sumitomo Chemical, Kracie to Codevelop Scabies Treatment  
- BioComber Licenses Cell-Free Protein Synthesis Technology to Chugai
- 17 **Survey**  
- 60% of ED Treatments Sold Online Are Counterfeits

## OPINION

- 18 **OPINION**  
- Benefits of an Attitude of Gratitude: Philip Carrigan

## MEDICAL FACILITIES & NURSING CARE

- 19 DPP-4/GLP-1 Drugs Need Further Assessment in Actual Medical Practice: Prof. Niki
- 19 Taxotere to Become New Treatment Option for Prostate Cancer: Prof. Akaza
- 20 Symbicort Renovates Asthma Treatment in Japan: Prof. Adachi
- 20 OAB Is Still Undertreated: Prof. Takahashi
- 22 Use of Biologics Recommended at an Early Stage for RA
- 22 JCR to Verify Acceptability of New ACR/EULAR RA Criteria in Japan
- 23 Children with New-Type Flu Not Treated with Tamiflu May Show Abnormal Behavior
- 23 Role of DPC Hospitals Needs to Be Reconsidered: Councillor Karasawa